INTRODUCTION
Awareness that patients with chronic lymphocytic leukemia (CLL) remain at risk of a poor outcome following chemotherapy has sparked a great deal of interest in understanding the pathophsyiology of this unique malignancy. Contrary to the long-held belief that it results from the accumulation of B lymphocytes, the latest data 1 adds credence to the view that the high growth rate of tumor cells has been overtaken by defective programmed cell death (PCD). Put simply, malignant B lymphocyte production is not offset by a commensurate order of cell eradication.
Improvement of immunotherapy-mediated cellular cytotoxicity would then be of value in the management of CLL patients. In this respect, a wealth of evidence has made CD20 an ideal target for B cell-depleting antibodies (Ab). 2 Supporting this assumption is that the first monoclonal Ab (mAb) approved by the Food and Drug Administration 3 to treat patients with non-Hodgkin's lymphoma (NHL) was specific for CD20. This was termed rituximab (RTX), validated as a therapy for NHL, and subsequently tested in CLL with a low response rate. 4 Diverging response rates may reflect low membrane expression of CD20 in CLL, compared with NHL. 5 This lack of efficacy prompted us to investigate in vitro further CD20-specific mAb. Among them, B1 (later called tositumomab) appeared to act by lysing a range of RTXresistant target B cells, including human CD20-transgenic B lymphocytes in mice. 6 Theoretically, the antitumor effects of CD20-specific mAb 7 combine Ab-dependent cellular cytotoxicity, complement-mediated lysis, and excessive PCD. For these mechanisms of action to proceed, the CD20 molecules must be cross-linked, and hence translocated into liquid-ordered structures of the membrane. 8 Some of them orchestrate B cell antigen receptor signaling. They have been denominated lipid rafts, of which the definition is strictly operational, based on insolubility in 1% Triton X-100 and buoyancy on density gradients. 9 These regions are not uniform, consisting of cholesterol and glycosphingolipids (GSL), such as ganglioside M1 (GM1) and sphingomyelin (SM). 10 This does not imply that SM is confined to the lipid rafts. Of interesting note is that SM can be hydrolyzed into ceramide by sphingomyelinases. In turn, ceramide is converted into SM by SM synthases 1 and 2. In practice, the lipid rafts may be detected in the plasma membrane using either cholera toxin B (CTB) which recognizes GM1, or with Ab directed against SM-bound lysenin. 11 Aggregation of CD20 activates the phosphoprotein associated with GSL which recruits Csk to the lipid DOI: 10.3324/haematol.2011.051938 rafts to keep the resident Src-family kinases inactive. 12 This adaptor has, accordingly, been termed Csk-binding protein (Cbp).
Recent reports have outlined the importance of membrane microdomains in the effect of RTX, in that CLL cells from patients with high GM1 expression respond to this mAb, whereas the remainder do not. 13 In this respect, following their landmark studies, 14 Cragg and colleagues have distinguished the type-I "RTX-like mAb" which translocate CD20 into lipid rafts and promote complement-mediated lysis, from the type-II "B1-like mAb" which do not translocate CD20 into conventional lipid rafts, but encourage PCD. 6 One step further, according to the same group of investigators, type-II mAb evoke homotypic adhesion of B cells, 6, 15 so that membrane exchanges brought about by cell-cell contacts through GSLcontaining microdomains cause a possibly non-apoptotic death. 16 Anyway, it has never been formally proven what molecular process in vivo might mimic the high-affinity crosslinking achieved with mAb reagents in vitro. 2 Paradoxically, a few CD20-specific mAb are extremely poor at inducing apoptosis, although potent at partitioning CD20 into membrane rafts, 15 and CD20 modulation limits the efficacy of related mAb. 17 Ultimately, so great are disparities in mechanisms induced by CD20-specific mAb to kill B lymphocytes, 18 that their heterogeneity casts doubt on a classification of CD20-specific mAb based solely on their ability to translocate their target antigen into the lipid rafts. In fact, there is no solid evidence that all membrane microdomains fulfill the criteria artificially chosen for the definition of lipid rafts. 19 Such statement is particularly worrisome because the results of the detergent-based methods used to purify lipid rafts may not reflect the overall membrane organization. Besides, lysis buffers other than Triton X-100 yields new microdomains similarly associated with CD20 molecules, 19 and the B1 mAb carry supplemental CD20 molecules into new insoluble fractions of the plasma membrane. 20 In light of what has recently been learned about the plasma membrane, we set out to dissect the relationships between the amount of GSL and the degree of cell destruction caused by B1 mAb. Based on our results, the CLL patients fell into two groups: one was sensitive and the other resistant to B1. To substantiate divergences, we showed that the plasma membrane of B cells from the former CLL patients contained Cbp and comprised much SM and GM1, whereas that of B cells from the latter lacked Cbp and comprised less GM1 and SM. In fact, SM was normally synthesized within the cell, but not exported to their plasma membrane, due to a default in the lipid translocase P-glycoprotein (P-gp), a transmembrane efflux pump. 21 Supporting such model, rifampicin-induced stimulation of P-gp raised the expression level of SM in the plasma membrane, 22 and thereby converted the formerly B1-resistant into B1-sensitive B cells.
DESIGN AND METHODS

Patients, disease and normal controls
Thirty-six untreated patients fulfilling the criteria for the diagnosis of CLL 23 were enrolled in the study, and scored clinically according to Matutes and colleagues. 24 At stage A, there were 13 men plus 12 women ranging in age from 50 to 91 years, at stage B two men plus two women ranging in age from 35 to 77 years, and at stage C four men plus three women ranging in age from 60 to 81 years (Supplementary Table 1 ). An additional 13 NHL patients, eight with marginal zone B cell (MZB) lymphoma, three with mantle cell lymphoma (MCL) and two with follicular lymphoma (FL), were included as disease controls for activity of the B1 mAb in low-grade NHL. 25 Blood was also taken from three healthy volunteers from the staff, and tonsils from four children undergoing routine tonsillectomy. it was feasible to confirm apoptosis was by cell morphology examination, enumeration of hypoploid cells, confocal microscopy examination of nuclear condensation and determination of poly (ADP-ribose) polymerase-cleavage products, using methods that we have previously validated and described.
26-28
Fluorescence-activated cell sorter analyses
In these studies, 5x10 5 freshly-isolated B cells were stained by incubation for 30 min at 4°C with saturating concentrations of conjugated anti-CD5, anti-CD19, anti-CD20 or anti-GM1 mAb. There was also unconjugated anti-ceramide mAb (Alexis) developed by FITC- permeabilized by a 20-min incubation at 4°C in PBS/bovine serum albumin (BSA) containing 0.5% saponin (Sigma). This cheap method gave similar results as treatment with a commercial kit. Intra-cytoplasmic lysenin was detected using the two-layer Ab system, as above.
Calculation of mean fluorescence intensities (MFI) of these markers required a minimum of 5,000 events and the results compared with isotype controls. As previously described as well, 28 the numbers of CD20 molecules per cell were indirectly quantified by determining the amount of mAb binding to the cells at saturating concentrations, using the Quantum kit (Flow Cytometry Standards Corp). Briefly, 50µL of microbeads were added to 20µL of mAb, and Ab-binding capacities (ABC) derived from the MFI and expressed as arbitrary units.
Confocal microscopy
In all these experiment, 3x10 5 B cells were stained by incubation for 15 min on ice with FITC-conjugated B1 mAb (Sigma). In the functional studies, this incubation was followed by a second 10-min incubation at 37°C. The consequential distribution of CD20 into the lipid rafts was studied by re-incubating the cells for 30 min at 4°C with biotinylated-CTB, or anti-lysenin pAb. After three washes with phosphate-buffered saline (PBS), the first lipid rafts marker was revealed by RRX-conjugated streptavidin, and the second by RRXconjugated goat anti-rabbit pAb. In some experiments, B cells were incubated with the FITCconjugated B1 mAb for 30 min on ice, and subsequently left at 37°C for another 7 min prior to their examination.
To access to intracellular Cbp, the lymphocytes were permeabilized using the Cytofix/cytoperm Fixation/Permeabilization kit (Becton-Dickinson) which gave much better pictures than incubation in saponin-containing PBS/BSA. The cells were then washed in PBS, and stained with mouse anti-Cbp mAb plus RRX-conjugated goat anti-mouse IgG pAb. The cells were then fixed with 4% paraformaldehyde, placed onto slides (Vector), cytospined at 300 rpm for 1 min, and visualized using a Leica TCS laser scanning confocal microscope equipped with the TCS NT Leica software.
Western blotting
Proteins were extracted from 2x10 7 The numbers of transcripts for CD20 were determined in 10 randomly-selected samples of CLL. We have also previously described the method we used here. 28 Briefly, the RNeasy Mini kit (Qiagen) served to extract mRNA. Quantitative RT-PCR was performed with the ABI PRISM 7,000 Sequence Dectector where the 18S rRNA gene enabled to normalize mRNA. Sequence of primers for the cd20 were 5'CCAATTACAGGG-CCTCGAAAG-3' plus 5'-CCAATTAC-AGGGCCTCGAAAG-3'.
Calcium flux measurements
We incubated 10 6 lymphocytes per mL for 20 min at 37°C with 5 µ M fluo-4 acetoxymethyl ester (AME), 0.02% pluronic acid, and 4 mM probenecid (Sigma). The cells were further maintained at 37°C for 30 min to de-esterificate intra-cellular AME. The cell suspension was then excited at 488 nm and stimulated with 25 µg/mL B1 mAb, instead of 10 µg/mL B1 mAb, like in other experiments, which did not induce reproducible calcium flux in pilot experiments. The MFI of AME at 525 nm was calculated. Treatment of the cells with 2 µg/mL ionomycin (Sigma) was taken as a positive control for these experiments.
Co-immunoprecipitation experiments
B lymphocytes from two B1-sensitive and two B1-resistant CLL patients were each distributed into three 1x10 7 -cell aliquots, and incubated with 2µg of anti-CD20 B1 mAb for 10 min. Importantly, the first aliquot was left at 4°C as a control for nonactivation through CD20, the second was incubated at 37°C, and the third was treated with rif for 30 min at 37°C, washed in PBS and incubated for another 10 min at 37°C with B1 mAb similar to the second cell aliquot. All the resulting pellets were washed again with PBS, and their proteins extracted by a 30-min incubation at 4°C in 1mL lysis buffer (Miltenyi). The debris were discarded by centrifugation for 15 min at 10,000 rpm and at 4°C, while protein G-coated beads were added to the supernatants. After 30 min at 4°C, they were washed four times with the buffer provided by Miltenyi, and once more with 100 mL Tris HCl 20µM. The beads were then mixed for 5 min with 20 µL of 95°C pre-treated Tris HCl, and applied onto a column.
This was washed with 60 mL of Tris HCl and its eluates resolved on 10% SDS-PAGE. After transfer of the proteins, the PVDF membranes were saturated with 5% non-fat milk in 10mM
Tris 0.1% Tween-20 (TBST) for 1 h, and washed three times with PBS. The proteins were revealed with mouse anti-CD20 mAb, mouse anti-Cbp mAb, rabbit anti-Lyn pAb (SantaCruz), rabbit anti-phospho-Lyn pAb (Abcam), or mouse anti-Syk mAb (Santa-Cruz) for 1 h.
The membranes were washed with TBST, all bound unconjugated Ab were incubated with HRP-labeled donkey anti-mouse IgG Ab or HRP-labelled donkey anti-rabbit IgG pAb, and binding revealed using ECL.
Determination of the P-gp transport activity
To determine the capability of P-gp to efflux GSL, we utilized rho123, as described by Fontaine, Elmquist and Miller. 29 Four aliquots of 5x10 5 B lymphocytes from three patients with NHL, four patients with B1-sensitive and four with B1-resistant CLL were incubated with 10µg/mL of rho123 for 90 min. All aliquots were then washed in PBS before FACS analysis. The first aliquot was studied immediately, the second after 15 min, the third after 30 min, and the fourth after 60 min. In one experiment, B lymphocytes were incubated again with rif for 30 min at 37°. Then, the amount of SM and P-gp, as well as the P-gp transport efficiency were re-evaluated.
Statistical analysis
Data were expressed as mean ± SD. Comparisons were made using the Fisher's test, the Mann-Whitney's test for unpaired data and the Wilcoxon's test for paired data. The correlations were established using Spearman's test.
RESULTS
The B1 mAb does not kill malignant cells in all CLL patients
We first wanted to ensure that the B1 mAb was a type II CD20-specific mAb, by assessing its inability to induce complement-mediated lysis. 6, 14 Such was the case, as the results showed that its killing activity was not impaired by removal of complement (data not shown). Further experiments confirmed that, without any crosslink, like RTX-like type I CD20 mAb, 30 the B1 mAb did not induce calcium flux, although ionomycin mobilized calcium normally in the B lymphocytes studied ( Figure 1A ).
Based on the behavior of the malignant B lymphocytes to B1-induced PCD (with a cut-off value set at 10% according to spontaneous apoptosis, as previously reported 28 were not different in the 10 randomly-selected CLL patients, then identified as belonging to one of the two CLL groups described above: 0.20±0.37 in three B1-sensitive versus 0.24±0.30
in seven B1-resistant CLL patients. Thus, the expression of CD20 does not influence the B1-induced death of B cells, in contrast to the dependence of RTX-induced cell death on CD20 density. 31, 32 Since responsiveness to RTX correlates with the CD20 density and with the severity markers, 32 dissociation between the responsiveness to B1 and the CD20 density is consistent with the absence of associations (Supplementary Relevance of the membrane structure to the B1-induced cell death
Besides the division of the CLL into responders and non-responders according to their vulnerability to the B1 mAb, the notion that the extent of B1-induced cell death depends on the capacity of this mAb to translocate CD20 into LR. 16, 18 raises the possibility that differences between B1-sensitive and B1-resistant CLL patients reflect variations in membrane expression of GM1 on their B cells.
The results provided evidence for this working hypothesis (Figure 2A ) . Thus, the MFI of lipid rafts-bound FITC-conjugated CTB were much higher in the B lymphocytes from the former group than in those from the latter: 3.1±1.1 versus 1.6±0.3 (P<10 -4 ). That is, B cells from the B1-sensitive CLL patients went to have similar amounts of GM1 as those from MZB lymphoma patients in contrast to those from the B1-resistant CLL patients. Of note in Figure   2A was that CTB binding distinguished five cases with the highest levels of GM1, from 14 cases in the B1-sensitive CLL. At the moment, such dichotomy between patients is unclear, but deserves further experimental evaluation. These FACS analysis results were confirmed by Western blotting (close to the two MZB lymphomas, compare the five B1-sensitive to the four B1-resistant CLL patients in Figure 2B ), and further documented by confocal microscopy examination of total GM1. This is evident from comparing the medium to the bottom panel of the second column in Figure 2C for GM1, and the top to the bottom panel of the second column in Figure 2D for SM.
Additionally, confocal microscopy showed that, given their normal membrane expression of GM1, B cells from patients with MZB lymphoma and B1-sensitive CLL were capable of partitioning the B1-bound CD20 molecules into GM1-enriched domains, possibly lipid rafts. At first glance, this data is at odds with previous reports, but it has to be kept in mind than lipid raft GSL could not be distinguished from non-lipid raft GSL in our experiments. 6, 16 Figure 2C shows that green-stained CD20 spots and red-stained GM1 spots merged, so that their overlays turned yellow (third column).
SM could be relevant to B1-triggered PCD. Their involvement was supported using confocal microscopy as B1 and SM co-localized in B1-sensitive, but not in B1-resistant CLL patients ( Figure 2D ). In contrast, the lack of GM1 in the B lymphocytes from B1-resistant CLL patients was associated with their dysfunction. As can be seen, B1 did not co-localize CD20 with GM1, since the green CD20 spots kept distinct from the red GM1 spots (third column).
On the basis that GM1 is synthesized from ceramide, a decrease in the amount of intracellular ceramide might lead to reduced synthesis of GM1 in B cells from B1-resistant CLL patients. Unexpectedly, there were no differences between B1-resistant and B1-sensitive CLL patients in ceramide synthesis ( Figure 3A ) .Furthermore, FACS analyses were carried out to determine expression levels of SM at the outer leaflet of the cell membrane ( Figure 3B ). Figure 3D ) were seen by quantitative RT-PCR in the two groups of CLL patients.
The Cbp expression is downregulated in B cells from B1-resistant CLL patients
Compared with B1-resistant CLL patients, the abundance of GM1 and SM in B cells from B1-sensitive patients suggests that a specific lipid organization of the outer leaflet of the plasma membrane is mandatory for recruiting proteins to its inner leaflet. Of these organizations, some are implicated in the transduction of CD20-mediated signals for PCD, most notably the transmembrane efflux pump Cbp. There appeared on the blots that Cpb was as highly expressed in five B1-sensitive CLL patients than in two patients with NHL, but far less in those from four B1-resistant CLL patients. It is interesting that Cbp co-localized with CD20 in the B lymphocytes from the B1-sensitive, but not in those from the B1-resistant CLL patients (compare the upper to the lower row in Figure 4A ).
The consequence was that stimulation of CD20 with the B1 mAb encouraged CD20 to interact with Cbp in B1-sensitive, but not in B1-resistant CLL patients, as confirmed by the co-immunoprecipitation experiments ( Figure 4C ). Once precipitated, B1-bound CD20 carried along with it Lyn in the two groups of patients. Of important note, the B1-sensitive, but not the B1-resistant CLL patients, showed Lyn partially phosphorylated and associated with Syk.
P-gp is essential for the transportation of SM to the plasma membrane
Given the role of P-gp in the extrusion of lipids across the plasma membrane, 33 we reasoned that the failure to translocate SM from the cytoplasm to the plasma membrane in B
lymphocytes from some CLL patients may reflect ineffectiveness of the pump. Due to the retention of SM within their cytoplasm, the membrane levels of P-gp were dramatically Remarkably, following P-gp induction with rif, the membrane expression levels of SM were augmented (P<0.01) to such an extent that there were no differences any more in the quantity of SM between untreated or rif-treated cells from B1-sensitive CLL patients on the one hand, and rif-treated cells from B1-resistant CLL patients on the other ( Figure 6A ).
Accordingly (please, have a look back at the right lanes in Figure 4C) , B1-stimulated CD20 co-immunoprecipitated Cbp, while Lyn was phosphorylated and accompanied by Syk. Thus, increasing amounts of SM conferred on CD20 the capacity to colocalize with SM ( Figure   6B ), as well as with Cbp ( Figure 6C ). As a result ( Figure 6D ), the B1-induced PCD was restored in these B lymphocytes, while cells originally resistant to the mAb turned out to be sensitive and thereby induced into apoptosis (P<0.01). These results suggest that the lack of SM is sufficient to keep apoptosis at bay.
DISCUSSION
The present study is the first to confirm and extend that B cells diverge from one CLL patient to another with respect to their membrane lipid organization, as originally described by Meyer zum Büshenfelde and colleagues. 13 Such an observation must be of practical importance, inasmuch as efficiency of biotherapies depends on lipid distribution in the plasma membrane. 34 Its relevance is further exemplified by a recent study showing that edelfosine triggers apoptosis of malignant B cells by clustering Fas within the lipid rafts, 35 and that the deficiency of SM in lymphoma patients prevents stabilization of Fas into the lipid rafts, thereby hindering the efficacy of the drug. 36 In the current work, CLL B cells characterized by high GM1 and SM levels in their plasma membrane possessed active P-gp pumps, recruited Cbp, and ultimately were sensitive to B1 mAb-induced PCD. This holds true for half of the CLL patients and for all those with NHL. In contrast, B cells from certain CLL patients exhibited a downregulated membrane expression of GM1 and SM. The local defect was assigned to intracytoplasmic accumulation of GSL, rather than its insufficient synthesis. The cause was a lowered transport by the efflux pumps from the cytoplasm to the plasma membrane. Confirming our proposition, rif-induced activation of P-gp increased SM at the outer leaflet of the membrane, and, by doing so, facilitated recruitment of Cbp. In other words, it is the distribution of SM that governs the attraction of Cbp to the membrane.
Likewise, RTX has been claimed to activate the SM cycle in lymphoma B cells with intracellular ceramide production, mainly due to SM hydrolysis by sphingomyelinase stimulation. 37 Interestingly, B1-mediated activation of lymphocytes does not influence the synthesis of ceramide, which suggests that variations in its killing efficacy are likely to be due to differences in the lipid organization at the outer leaflet of the plasma membrane. The implication of this influence is that several types of microdomains and/or lipid rafts must exist. As a matter of fact, they would display distinct properties, and react differently in the presence of 1% Triton X-100. Moreover, the interrelationships between these distinct structures may modulate response to CD20-specific mAb. Similar characteristics have been ascribed to Fas-induced apoptosis which can be regulated at the membrane level by lipid rafts in T lymphocytes. 38 Alternatively, the GSL identified above might belong to the non-raft, rather than to the raft areas. Thus, in CD5-expressing CLL B lymphocytes differences have also been described in the proapoptotic activity of anti-CD5 mAb, 28, 39 and also attributed to the composition of membrane microdomains and their subsequent association with specific proteins.
We believe that other GSL or precursors of GM1 are accumulating upstream. Some of these structures are present with high metastatic potential in cancer. 40, 41 This raises the issue that certain B1-resistant CLL may consist of tumor cells that warrant further characterization.
At the moment, our results show that the total amount of SM is the same in the two groups of CLL patients. Consequently, should SM lacks at the external membrane, the missing SM is sequestrated within intracellular compartments. In agreement with this view, P-gp has the capacity to induce translocation of lipids, such as SM and glucosylceramide, across the plasma membrane. One step further, differences in P-gp activity distinguish B cells of a given patient with CLL from another, 42, 43 and the present study associates these cells with the susceptibility to B1-induced PCD.
Simply, on the basis that B1 does not proceed through conventional lipid rafts, this mAb is distinguished from RTX, and grouped as a type II anti-CD20 mAb. Yet, a major concern exists regarding the definition of lipid rafts, which relies historically on insolubility in 1% Triton X-100. 9, 44 As strongly highlighted by Pike, 45 a number of other detergents have since been used to isolate membrane fractions, and the protein and lipid content of lipid rafts prepared by these various methods shown to display significant differences, suggesting that they do not yield identical membrane fractions. Non-detergent methods have also been developed for isolating lipid rafts. 46 According to some investigators, detergent resistance would even be a highly subjective approach. 47 This claim is based on differences in the results of numerous studies strongly support that lipid rafts are not uniform. 48 Such heterogeneity might thus account for disparities in their definition of lipid rafts, and discrepancies on their requirement for anti-CD20 on Ab-induced apoptosis.
In line with this cautions interpretation, our fluorescence-based experiments revealed that, in B cells from patients with B1-sensitive CLL and NHL, B1 co-localizes CD20 with SM, GM1 and Cbp. Moreover, in B cells from B1-resistant CLL patients, where SM was reduced at the cell surface, rif promoted P-gp, and improved co-localization. So, this antibiotic increases the level of SM and thereby enables its association with CD20 and Cbp in B cells from B1-resistant CLL patients. Finally, PCD reappeared after rif treatment in these CLL B cells after incubation with B1 mAb. Very interestingly, to explain their seminal finding that B1 does not activate caspases, Ivanov and colleagues speculated that it may operate in a non-apoptotic way, 15, 16 which is difficult to reconcile with findings of others. 49 In fact, these differences may simply be accounted for by specificities of the various techniques used by these investigators. 50 Nonetheless, the present results confirm that the B1 mAb produces direct cytotoxic effects in B cells from some CLL patients, regardless of apoptotic or non-apoptotic mechanisms.
To conclude, our findings indicate that membrane lipids are crucially implicated in the survival of CLL B cells following treatment with depleting mAb. Clearly, these data provide new insights into understanding of CLL physiopathology, and may help predict the efficiency of related therapies.
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B1-resistant CLL
